Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, 710038 Xi'an, PR China.
Diagn Pathol. 2013 Aug 28;8:145. doi: 10.1186/1746-1596-8-145.
This article aims to investigate the expression of vacuolar-H + -ATPase (V-ATPase) in non-small cell lung cancer (NSCLC) and its variations with pathological type and grade. Furthermore, to evaluate the chemotherapy drug sensitivity of different cancer tissues as well as its correlation with V-ATPase expression in NSCLC.
V-ATPase expression was examined in 92 NSCLC tissue samples using the immunohistochemical Envision method and immunofluorescence assay. The location of V-ATPase expression was observed by confocal laser scanning microscopy and the difference of its expression rate was evaluated. The sensitivity of cancer tissues to chemotherapy drug was examined using MTT assay and its correlation with the V-ATPase expression was tested in NSCLC by Spearman rank correlation analysis.
V-ATPase expression was mainly localized in the cell membrane and cytoplasm. The expression rate of V-ATPase was 71.43% in squamous cell lung cancer, significantly lower than that of the lung adenocarcinoma (83.72%, P = 0.000). In different pathological grades of squamous cell lung cancer, the expression rate of V-ATPase was 58.33% in grade II, significantly lower than that of the grade III (84.00%, P = 0.014). The expression rate of V-ATPase in grade II lung adenocarcinoma was 76.67%, significantly lower than that of the grade ΙΙΙ adenocarcinoma (100.0%, P = 0.012). Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05).
V-ATPase was overexpressed in NSCLC. The expression of V-ATPase was related to the pathological type and grade of cancer and was likely associated with chemotherapy drug resistance in NSCLC.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7515811511020000.
本文旨在研究空泡质子泵（V-ATPase）在非小细胞肺癌（NSCLC）中的表达及其与病理类型和分级的变化。此外，评估不同癌组织的化疗药物敏感性及其与 NSCLC 中 V-ATPase 表达的相关性。
采用免疫组织化学 Envision 法和免疫荧光法检测 92 例 NSCLC 组织中 V-ATPase 的表达，应用共聚焦激光扫描显微镜观察 V-ATPase 的表达部位，评估其表达率的差异。采用 MTT 法检测癌组织对化疗药物的敏感性，并采用 Spearman 秩相关分析检测 NSCLC 中 V-ATPase 表达与化疗药物敏感性的相关性。
V-ATPase 主要定位于细胞膜和细胞质。V-ATPase 在鳞癌中的表达率为 71.43%，明显低于肺腺癌（83.72%，P=0.000）。在不同病理分级的鳞癌中，V-ATPase 在Ⅱ级的表达率为 58.33%，明显低于Ⅲ级（84.00%，P=0.014）。Ⅱ级肺腺癌中 V-ATPase 的表达率为 76.67%，明显低于Ⅲ级腺癌（100.0%，P=0.012）。相关性分析显示，NSCLC 组织对环磷酰胺、吉西他滨、阿霉素、紫杉醇和顺铂的敏感性与 V-ATPase 表达率呈显著相关（P<0.05）。
V-ATPase 在 NSCLC 中过度表达。V-ATPase 的表达与癌症的病理类型和分级有关，可能与 NSCLC 化疗耐药有关。
